The Best of FierceBiotech 2010

Over the past year, a steadily growing life sciences team at FierceMarkets has presented a long lineup of special reports on the biopharma industry. Some you're familiar with; for instance, this year marked our eighth annual Fierce 15. But we also followed up with new reports on some novel subjects, such as the most notable women in biotech or a look at the top Phase III failures of the year and much, much more.

Today's issue is dedicated to our most popular special reports of the year. Check them out and let us know what you'd like to see in 2011. - John Carroll (email | twitter)

P.S. For those of you who don't subscribe to our newsletter, you can see all of the 2010 special reports here.

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.